142 related articles for article (PubMed ID: 38828336)
1. ANGPTL3 diminishes the resistance of ovarian cancer to paclitaxel by blocking the PI3K-AKT-mTOR signaling pathway.
Wu D; Liu J; Yang X; Wu Z; Wang T; Xiao M
Heliyon; 2024 Jun; 10(11):e31520. PubMed ID: 38828336
[TBL] [Abstract][Full Text] [Related]
2. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
3. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
4. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
5. Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway.
Wu Y; Liu X; Qin Z; Hu L; Wang X
Onco Targets Ther; 2018; 11():5621-5630. PubMed ID: 30254455
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
7. OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway.
Xie W; Yu J; Yin Y; Zhang X; Zheng X; Wang X
Front Oncol; 2022; 12():876257. PubMed ID: 36033461
[TBL] [Abstract][Full Text] [Related]
8. Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway.
Qiao J; Wang WJ; Zhang Y
Oncol Lett; 2018 Nov; 16(5):6417-6422. PubMed ID: 30405778
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway.
Li G; Xu D; Sun J; Zhao S; Zheng D
Adv Clin Exp Med; 2020 Nov; 29(11):1337-1345. PubMed ID: 33269821
[TBL] [Abstract][Full Text] [Related]
10. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis.
Li M; Cai J; Han X; Ren Y
Cancer Manag Res; 2020; 12():9159-9171. PubMed ID: 33061608
[TBL] [Abstract][Full Text] [Related]
12. Circ_0000231 promotes paclitaxel resistance in ovarian cancer by regulating miR-140/RAP1B.
Liu J; Wang H; Xiao S; Zhang S; Qi Y; Wang M
Am J Cancer Res; 2023; 13(3):872-885. PubMed ID: 37034216
[TBL] [Abstract][Full Text] [Related]
13. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
[TBL] [Abstract][Full Text] [Related]
14. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Weng H; Feng X; Lan Y; Zheng Z
J Ovarian Res; 2021 Jun; 14(1):82. PubMed ID: 34162426
[TBL] [Abstract][Full Text] [Related]
15. Tetrandrine Reverses Paclitaxel Resistance in Human Ovarian Cancer via Inducing Apoptosis, Cell Cycle Arrest Through β-Catenin Pathway.
Jiang L; Hou R
Onco Targets Ther; 2020; 13():3631-3639. PubMed ID: 32431514
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
17. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
19. Cyclin dependent kinase 14 as a paclitaxel-resistant marker regulated by the TGF-β signaling pathway in human ovarian cancer.
Guan W; Yuan J; Li X; Gao X; Wang F; Liu H; Shi J; Xu G
J Cancer; 2023; 14(13):2538-2551. PubMed ID: 37670966
[TBL] [Abstract][Full Text] [Related]
20. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
